Scholarlink

Introduction <p>Tardive dyskinesia (TD) is a disabling movement disorder induced by prolonged administration of dopamine receptor–blocking agents, primarily high-potency first-generation antipsychotics.</p> Case presentation <p>We report the case of a 32-year-old Iranian male patient with schizophrenia who developed TD following treatment with the second-generation antipsychotic aripiprazole. The patient experienced involuntary facial and jaw movements that started about four weeks after he abruptly discontinued the drug on his own. While there was a generally reduced risk of extrapyramidal symptoms with second-generation antipsychotics, the patient’s symptoms were clinically significant and impacted his quality of life. Initial management efforts were not beneficial; however, after adjustment of the previous antipsychotic therapy and introduction of tetrabenazine, a VMAT2 inhibitor approved for TD, the patient showed marked symptomatic improvement.</p> Conclusion <p>This case emphasizes clinical awareness of the possibility of risk for tardive dyskinesia despite atypical antipsychotics such as aripiprazole and the therapeutic value of tetrabenazine as an important treatment option for this intractable condition.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Management of severe tardive dyskinesia induced by arpiprazole in a schizophrenic patient: a case report

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月20日

查看全文
  • Farzad Fayedeh,
  • Mahya Mojahedi,
  • Danial Gharaie Amirabadi

摘要

Introduction

Tardive dyskinesia (TD) is a disabling movement disorder induced by prolonged administration of dopamine receptor–blocking agents, primarily high-potency first-generation antipsychotics.

Case presentation

We report the case of a 32-year-old Iranian male patient with schizophrenia who developed TD following treatment with the second-generation antipsychotic aripiprazole. The patient experienced involuntary facial and jaw movements that started about four weeks after he abruptly discontinued the drug on his own. While there was a generally reduced risk of extrapyramidal symptoms with second-generation antipsychotics, the patient’s symptoms were clinically significant and impacted his quality of life. Initial management efforts were not beneficial; however, after adjustment of the previous antipsychotic therapy and introduction of tetrabenazine, a VMAT2 inhibitor approved for TD, the patient showed marked symptomatic improvement.

Conclusion

This case emphasizes clinical awareness of the possibility of risk for tardive dyskinesia despite atypical antipsychotics such as aripiprazole and the therapeutic value of tetrabenazine as an important treatment option for this intractable condition.